ALX Oncology (ALXO) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
ALX Oncology (ALXO) has outperformed Upstream Bio (UPB) over the past year, losing 29.3% versus a loss of 86.8%. Upstream Bio is the larger company by market cap ($151.2 million vs $146.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | UPB |
|---|---|---|
| Share price | $1.06 | $2.76 |
| Market cap | $146.57M | $151.17M |
| 1-day change | +6.00% | -18.10% |
| YTD return | -6.19% | -89.83% |
| 1-year return | -29.33% | -86.84% |
| 5-year return | -98.04% | — |
| EPS (TTM) | $-1.13 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.85M |
| Revenue growth (YoY) | — | +20.42% |
| Net income (latest FY) | $-101.69M | $-143.44M |
| Operating margin | — | -5618.82% |
| Net margin | — | -5026.03% |
| 52-week high | $2.66 | $33.68 |
| 52-week low | $0.862 | $2.74 |
| Distance from 52-week high | -60.15% | -91.81% |
| Analyst consensus | none | none |
| Avg. price target upside | +333.96% | +1028.26% |
| Average volume | 1.15M | 734.05K |
| Shares outstanding | 138.28M | 54.77M |
| Employees | 48 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed UPB by 57.5 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
ALXO vs UPB FAQ
Which is bigger, ALX Oncology or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $151.17M compared with $146.57M for ALX Oncology (ALXO).
Which stock has performed better over the past year, ALXO or UPB?
ALXO returned -29.33% over the past 12 months, compared with -86.84% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.